Multimorbidity Treatment Burden Questionnaire (MTBQ): Translation, Cultural Adaptation, and Validation in French-Canadian

Reliable treatment burden measures are needed given the aging population and the associated increase in multimorbidity and polypharmacy. Treatment burden is defined as the effort to care for one’s health and the resulting impact on one’s daily life. This study aimed to translate the Multimorbidity T...

Full description

Saved in:
Bibliographic Details
Published in:Canadian journal on aging 2023-03, Vol.42 (1), p.126-134
Main Authors: Guénette, Line, Turcotte, Véronique, Bélanger, Laurianne, Blais, Lucie, Sirois, Caroline, Lunghi, Carlotta, Duncan, Polly
Format: Article
Language:English
Subjects:
Activities of daily living
Adaptation
Aged
Aging
Bilingualism
Canada
Chronic illnesses
Comorbidity
Coronaviruses
Cross-Cultural Comparison
Debriefing
Everyday life
French Canadians
French language
Health care
Health services
Humans
Multimorbidity
Older people
Polypharmacy
Population growth
Prescription drugs
Psychometrics
Quality of Life
Quantitative psychology
Questionnaires
Reliability
Reproducibility of Results
Surveys and Questionnaires
Translation
Translations
Treatment needs
Validation studies
Validity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Reliable treatment burden measures are needed given the aging population and the associated increase in multimorbidity and polypharmacy. Treatment burden is defined as the effort to care for one’s health and the resulting impact on one’s daily life. This study aimed to translate the Multimorbidity Treatment Burden Questionnaire (MTBQ) for French-Canadians and assess its reliability and validity. The MTBQ was translated and tested with cognitive debriefing interviews, and the French version (MTBQ-F) was then administered 2 times among 105 participants. Reliability and validity were examined using the intra-class correlation coefficient (ICC), Cronbach’s alpha, and Spearman’s correlations. The median global MTBQ-F scores were 32.69 (interquartile range [IQR]: 21.15-48.08) and 30.77 (IQR: 21.15-46.15) for the first and second administrations, respectively. Test-retest (ICC: 0.73; 95% CI: 0.63-0.81) and internal consistency reliability (Cronbach’s alpha: 0.80) were good. There was a moderate positive correlation between the MTBQ-F score and the number of self-reported conditions (rho: 0.28). This valid instrument could identify patients experiencing a high treatment burden and assess the impact of interventions among them.
ISSN:0714-9808
1710-1107
DOI:10.1017/S0714980822000058